PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3866254-0 1985 Vasoactive intestinal polypeptide acts synergistically with norepinephrine to depress spontaneous discharge rate in cerebral cortical neurons. Norepinephrine 60-74 vasoactive intestinal peptide Rattus norvegicus 0-33 2852216-5 1988 Simultaneous addition of VIP or secretin to the Schwann cell culture synergistically enhanced the norepinephrine-induced elevation of intracellular cyclic AMP. Norepinephrine 98-112 vasoactive intestinal peptide Rattus norvegicus 25-28 20501252-3 1988 When applied simultaneously with adenosine or noradrenaline, VIP depressed the firing of cortical neurons, but this depression could be reproduced by the passage of similar positive currents through a 50 mM NaCl-containing barrel of the multiple barrelled micropipette. Norepinephrine 46-59 vasoactive intestinal peptide Rattus norvegicus 61-64 20501252-5 1988 Leakage of adenosine or noradrenaline during iontophoretic applications of the peptide may account for the reported inhibitory actions of VIP. Norepinephrine 24-37 vasoactive intestinal peptide Rattus norvegicus 138-141 6473156-7 1984 Norepinephrine (5 micrograms/kg/min) also reversed the effect of VIP on the small intestine and colon. Norepinephrine 0-14 vasoactive intestinal peptide Rattus norvegicus 65-68 6089134-6 1984 These findings are consistent with a hyperactivity of norepinephrine pathways in spontaneously hypertensive rats, leading to a reduced number of cardiac post-junctional secretin/VIP receptors bound to adenylate cyclase. Norepinephrine 54-68 vasoactive intestinal peptide Rattus norvegicus 178-181 2863199-3 1985 Infusion of noradrenaline, an alpha-adrenergic agonist, inhibited basal and vasoactive intestinal polypeptide (VIP) stimulated flow rate and output of EGF from Brunner"s glands and increased the amount of EGF in the tissue. Norepinephrine 12-25 vasoactive intestinal peptide Rattus norvegicus 76-109 2863199-3 1985 Infusion of noradrenaline, an alpha-adrenergic agonist, inhibited basal and vasoactive intestinal polypeptide (VIP) stimulated flow rate and output of EGF from Brunner"s glands and increased the amount of EGF in the tissue. Norepinephrine 12-25 vasoactive intestinal peptide Rattus norvegicus 111-114 2863199-6 1985 The presence of PAS-positive mucus in Brunner"s glands was unchanged during infusion of noradrenaline whereas VIP induced a depletion of Brunner"s gland mucus which in turn was prevented by simultaneous infusion of noradrenaline. Norepinephrine 215-228 vasoactive intestinal peptide Rattus norvegicus 110-113 6473156-0 1984 Angiotensin II and norepinephrine antagonize the secretory effect of VIP in rat ileum and colon. Norepinephrine 19-33 vasoactive intestinal peptide Rattus norvegicus 69-72 6473156-2 1984 We assessed the ability of angiotensin II (AII) and norepinephrine (NE) to block the secretion evoked by VIP, in vivo. Norepinephrine 52-66 vasoactive intestinal peptide Rattus norvegicus 105-108 6195528-8 1983 Vasoactive intestinal peptide (VIP) on the other hand increases cyclic AMP in the absence of noradrenaline. Norepinephrine 93-106 vasoactive intestinal peptide Rattus norvegicus 31-34 6106694-6 1980 Biochemical analyses of the lesions suggested that loss of VIP action on adenylate cyclase was associated with loss of hypothalamic noradrenaline-containing neurons. Norepinephrine 132-145 vasoactive intestinal peptide Rattus norvegicus 59-62 19936638-11 2010 Sympathectomy induced a significant increase in dura mater NO levels and VIP decreased NO to control levels and increased the norepinephrine vessel-contraction responses of sympathectomized rats. Norepinephrine 126-140 vasoactive intestinal peptide Rattus norvegicus 73-76 222624-4 1979 beta-Endorphin, VIP, secretin, and glucagon all produce discrete changes in norepinephrine turnover in various hypothalamic nuclei. Norepinephrine 76-90 vasoactive intestinal peptide Rattus norvegicus 16-19 33220286-4 2021 KEY FINDINGS: In the cyclic animal in estrus, the treatment with Ant-VIP in the left ovarian bursa resulted in a reduction in testosterone serum levels and in ovarian levels of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC), without changes in 4-hydroxy-3-methoxyphenyl (MHPG) and norepinephrine (NE). Norepinephrine 286-300 vasoactive intestinal peptide Rattus norvegicus 69-72 11931349-4 2002 Combination of PACAP38, PACAP27 (each at 0.1 microM) and VIP (1 microM) with adrenaline or noradrenaline resulted in most cases in additive effects, with some supraadditive (PACAP27 plus adrenaline) or subadditive (PACAP38 or VIP plus noradrenaline) fluctuations. Norepinephrine 91-104 vasoactive intestinal peptide Rattus norvegicus 226-229 20150881-2 2010 In this work we investigate whether norepinephrine (NE) modifies the vasoactive intestinal peptide (VIP) or neuropeptide Y (NPY) actions in coeliac ganglion (CG) on the ovarian hormone release, and evaluate the participation of nitric oxide (NO), measured as nitrite, and of inducible nitric oxide synthetase (iNOS) protein, nerve growth factor (NGF) and its trkA receptor gene expression in the ovarian response. Norepinephrine 36-50 vasoactive intestinal peptide Rattus norvegicus 100-103 15567974-4 2004 RESULTS: In D1 ovaries, NPY, VIP or SP, both alone and with norepinephrine, generally decreased the release of Po. Norepinephrine 60-74 vasoactive intestinal peptide Rattus norvegicus 29-32 15567974-6 2004 In D2, NPY, VIP or SP, both alone and with norepinephrine, increased Po release. Norepinephrine 43-57 vasoactive intestinal peptide Rattus norvegicus 12-15 11931349-4 2002 Combination of PACAP38, PACAP27 (each at 0.1 microM) and VIP (1 microM) with adrenaline or noradrenaline resulted in most cases in additive effects, with some supraadditive (PACAP27 plus adrenaline) or subadditive (PACAP38 or VIP plus noradrenaline) fluctuations. Norepinephrine 235-248 vasoactive intestinal peptide Rattus norvegicus 57-60 10194528-3 1999 Using intact capsular tissue it was found that VIP caused a dose-dependent increase in aldosterone secretion, with a concomitant increase in both adrenaline and noradrenaline release. Norepinephrine 161-174 vasoactive intestinal peptide Rattus norvegicus 47-50 7830053-6 1995 As with forskolin and cholera toxin, physiological signaling molecules such as vasoactive intestinal polypeptide (VIP) and AMP, for which PC12 cells are known to have receptors linked to activation of adenylate cyclase, also inhibited norepinephrine uptake. Norepinephrine 235-249 vasoactive intestinal peptide Rattus norvegicus 79-112 9798735-8 1998 VIP has an additive effect at a lower (100 nM) concentration combined with norepinephrine (NE). Norepinephrine 75-89 vasoactive intestinal peptide Rattus norvegicus 0-3 9510417-1 1998 The intracortical organization of the noradrenaline (NA) and vasoactive intestinal polypeptide (VIP) systems provides ample opportunity for functional convergence, and accumulated evidence indicates that NA and VIP share certain cellular actions upon both neuronal and nonneuronal cortical elements. Norepinephrine 38-51 vasoactive intestinal peptide Rattus norvegicus 211-214 7830053-6 1995 As with forskolin and cholera toxin, physiological signaling molecules such as vasoactive intestinal polypeptide (VIP) and AMP, for which PC12 cells are known to have receptors linked to activation of adenylate cyclase, also inhibited norepinephrine uptake. Norepinephrine 235-249 vasoactive intestinal peptide Rattus norvegicus 114-117 7896056-0 1994 Effects of vasoactive intestinal peptide and its homologues on the noradrenaline-mediated secretion of fluid and protein from the rat submandibular gland. Norepinephrine 67-80 vasoactive intestinal peptide Rattus norvegicus 11-40 7896056-2 1994 Noradrenaline-mediated secretion of fluid and protein from rat submandibular glands was enhanced by vasoactive intestinal peptide (VIP) and secretin but not by peptide histidine isoleucine (PHI) or gastric inhibitory peptide (GIP). Norepinephrine 0-13 vasoactive intestinal peptide Rattus norvegicus 100-129 7896056-2 1994 Noradrenaline-mediated secretion of fluid and protein from rat submandibular glands was enhanced by vasoactive intestinal peptide (VIP) and secretin but not by peptide histidine isoleucine (PHI) or gastric inhibitory peptide (GIP). Norepinephrine 0-13 vasoactive intestinal peptide Rattus norvegicus 131-134 8190350-5 1994 Present data support the hypothesis that adrenaline and/or noradrenaline could mediate the effects of both NPY and VIP on aldosterone secretion via beta 1 adrenergic receptors; alternatively, the steroidogenic effect of NPY or VIP could be related to direct interaction between NPY- or VIP-specific binding sites, present on the capsule/glomerular zone of the rat adrenal cortex, and beta 1 adrenergic receptors. Norepinephrine 59-72 vasoactive intestinal peptide Rattus norvegicus 115-118 8006835-4 1994 The purpose of this study is to determine if ACh and VIP cause differential secretion of adrenaline and noradrenaline and whether the differential secretion also occurs when splanchnic nerves are stimulated at different frequencies. Norepinephrine 104-117 vasoactive intestinal peptide Rattus norvegicus 53-56 8006835-11 1994 Perfusion with VIP (10 microM for 4 min) resulted in the secretion of 27 ng of catecholamines and the ratio of adrenaline to noradrenaline was 9.7. Norepinephrine 125-138 vasoactive intestinal peptide Rattus norvegicus 15-18 8006835-12 1994 A higher concentration of VIP (20 microM for 4 min) resulted in the secretion of greater amounts of catecholamines (102 ng) without significantly altering the ratio of adrenaline to noradrenaline (10.9). Norepinephrine 182-195 vasoactive intestinal peptide Rattus norvegicus 26-29 1864314-3 1991 Simultaneously with the change in blood pressure and heart rate, the concentrations of plasma epinephrine and norepinephrine rose 4 and 10 min after VIP administration. Norepinephrine 110-124 vasoactive intestinal peptide Rattus norvegicus 149-152